ABION Inc. operates as a pharmaceutical biotech company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN901, ABN902, and ABN903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.

Targeted Cancer Therapies: ABION is developing ABN401, a tyrosine kinase inhibitor targeting c-Met, which is implicated in tumor growth and angiogenesis. ABN401 has shown a superior safety profile in Phase I clinical trials. Antibody Therapeutics: The company is advancing ABN501, a novel Claudin 3 (CLDN3) targeting monoclonal antibody with high specificity and strong binding affinity. Antibody-dependent cellular cytotoxicity (ADCC) activity against CLDN3-positive tumors was tested in vitro and in vivo. The pre-clinical trial is planned for 2023. Antiviral Therapies: ABION is developing ABN101, a broad-spectrum antiviral inhaler drug based on 2nd generation Interferon-β. The goal is to prevent infected patients from severity and hospitalization, improving patient convenience by stockpiling and distributing in the early phase of a pandemic.

Private

Biotech